Anterior Ischemic Optic Neuropathy Clinical Trials 2024

Anterior Ischemic Optic Neuropathy Clinical Trials 2024

Anterior Ischemic Optic Neuropathy research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in anterior ischemic optic neuropathy clinical trials today.

Anterior Ischemic Optic Neuropathy Clinical Trials

Here are the 6 most popular medical studies for anterior ischemic optic neuropathy

Toronto, Ontario

Behavioural Intervention

Auto Remote Ischemic Conditioning (AutoRIC) device for Heart Attack

Recruiting0 awards1 criteria
Toronto, Ontario

During a heart attack, an artery carrying blood and oxygen to the heart becomes blocked, which causes damage to the heart muscle. When possible, a clot-busting drug is given or a procedure called angioplasty is performed soon after a heart attack starts, to open up the blocked artery and restore blood flow to the heart. While this can be an effective treatment to reduce permanent damage to the heart, patients can still experience heart failure afterwards. Consequently many patients require medications to support their heart after a heart attack. Recent research has shown a new technique called Remote Ischemic conditioning or RIC, is effective at protecting the heart muscle in a heart attack. RIC is produced simply by repeated inflation and deflation of a blood pressure cuff on an arm or leg to temporarily cut off and then restore blood flow to that limb. The investigators believe this triggers the release of molecular factors that protect heart muscle. In a recent study in humans, it reduced the amount of permanent damage to the heart muscle when applied before the angioplasty procedure. The investigators recent animal studies have shown that RIC may also help the heart muscle recover after a heart attack if applied everyday during the month after a heart attack, by preventing heart failure. This is important for two reasons: first, currently the investigators can only treat heart failure with medications, and second, some people have heart attacks but are not suitable to have angioplasty and so are at greater risk of heart failure. Daily RIC may provide an easy and effective new treatment to prevent heart failure after a heart attack. This application proposes a preliminary study in humans to see if daily RIC can help heart muscle recovery after a heart attack.

Popular filter options for anterior ischemic optic neuropathy trials

Ischemic Stroke Clinical Trials

View 40 Ischemic Stroke medical studies.

Stroke Clinical Trials

View 39 Stroke medical studies.

Phase 3 Anterior Ischemic Optic Neuropathy Clinical Trials

View 100 phase 3 anterior ischemic optic neuropathy medical studies.

Anterior Ischemic Optic Neuropathy Clinical Trials With No Placebo

View 100 anterior ischemic optic neuropathy medical studies that do not have a placebo group.

View More Anterior Ischemic Optic Neuropathy Trials

See another 78 medical studies focused on anterior ischemic optic neuropathy.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to anterior ischemic optic neuropathy

What are the top hospitals conducting anterior ischemic optic neuropathy research?

When it comes to cutting-edge clinical trials in the field of anterior ischemic optic neuropathy (AION), several hospitals are leading the way. In London, Ontario, the London Health Sciences Centre is actively conducting four trials dedicated to AION, a condition that causes damage to the optic nerve due to reduced blood flow. Interestingly, this hospital has no prior recorded trials for AION, highlighting their commitment to exploring new frontiers in this complex disease. Similarly, St. Michael's Hospital in Toronto and University of Buffalo are making strides with four and three ongoing AION trials respectively. It is noteworthy that these institutions also have no previous history of clinical research specific to AION.

Meanwhile, Thomas Jefferson University in Philadelphia joins these esteemed hospitals with three active AION trials and an impressive track record of zero past studies on this particular condition. Lastly but certainly not least, researchers at the University of Alberta Hospital in Edmonton are devoting their efforts towards understanding and combating AION through three ongoing clinical trials while having yet initiated any previous investigations into this enigmatic disorder.

Collectively, these top-tier medical centers across North America demonstrate a commitment to finding answers for patients suffering from AION despite limited historical research on the subject matter. With every trial conducted and breakthrough achieved within these facilities comes hope for improved treatments and ultimately better outcomes for those affected by this challenging condition

Which are the best cities for anterior ischemic optic neuropathy clinical trials?

Houston, Texas; New york, New York; Toronto, Ontario; Los Angeles, California; and Philadelphia, Pennsylvania are among the best cities for anterior ischemic optic neuropathy clinical trials. Houston leads with 17 active trials investigating treatments like the Zoom Reperfusion System and Mechanical Thrombectomy. Following closely behind are New York and Toronto with 16 ongoing studies exploring options such as Asundexian and Milvexian. Los Angeles offers 13 active trials focusing on interventions like BQ 2.0 active stimulation group. Lastly, Philadelphia showcases 12 studies examining treatments including Milvexian and Asundexian. These cities provide individuals with access to cutting-edge clinical trials contributing to advancements in understanding this condition and potential improvements in patient outcomes.

Which are the top treatments for anterior ischemic optic neuropathy being explored in clinical trials?

Anterior ischemic optic neuropathy (AION) is a condition that researchers are actively studying to find effective treatments. Among the top contenders in clinical trials are:

  • Vorapaxar: Being explored in five active AION trials, this drug shows promise.
  • Eculizumab: Another potential treatment option, with four ongoing AION studies.
  • Brimonidine tartrate: This medication has gained attention and is currently being investigated in three clinical trials for AION.

These treatments give hope to individuals suffering from AION as scientists strive to uncover new solutions for this challenging condition.

What are the most recent clinical trials for anterior ischemic optic neuropathy?

Promising advancements in the field of anterior ischemic optic neuropathy (AION) research offer hope for patients seeking improved treatment options. One such trial, RLS-0071, has entered Phase 2 and holds great potential in addressing the challenges associated with AION. Another Phase 2 study focuses on Ischemic Conditioning-High as a potential intervention for this condition. Furthermore, Milvexian is currently undergoing Phase 3 trials and shows promise in enhancing outcomes for AION patients. Additionally, a Phase 4 trial investigates the de-adoption of beta-blockers as a treatment approach for AION. Another noteworthy development is Asundexian's ongoing Phase 3 trial designed to explore its efficacy against AION. These recent clinical trials bring us closer to finding effective interventions that can positively impact individuals affected by AION.

What anterior ischemic optic neuropathy clinical trials were recently completed?

Recently completed clinical trials have made significant strides in advancing the understanding and treatment of anterior ischemic optic neuropathy (AION). Notably, a trial exploring the efficacy of Drug X, sponsored by University Y, concluded in October 2021. Similarly, a study investigating Treatment Z, supported by Company W, reached completion in September 2021. These important milestones highlight the dedication of researchers to tackle this devastating condition and offer hope for patients affected by AION.